Background: Vulvovaginal candidiasis (VVC) is the second most common cause of vaginitis after bacterial vaginosis, and it is diagnosed in up to 40% of women with vaginal complaints in the primary care setting. Among Candida spp., Candida albicans is the most common infectious agent. The treatment of choice for uncomplicated VVC is achieved with single-dose or short-course therapy in over 90% of cases. Several topical and oral drugs are available, without evidence for superiority of any agent or route of administration. In any case, most classic treatments are unable to significantly offer a protection against possible recurrences. In recent years, probiotics are emerging as a new strategy to counteract VVC. In fact, they are well known for their ability to lower intravaginal pH, thus establishing a barrier effect against many types of yeasts. Some strains are also able to exert additional and more focused antagonistic activities mediated by specific molecules such as hydrogen peroxide and bacteriocins. For example, Lactobacillus fermentum LF5 (CNCM I-789) was successfully tested in 4 human trials involving a total of 340 women reporting VVC at enrollment. In any case, the way used to deliver probiotics to the vaginal environment represents a crucial point. The aim of this work was to first select 1 or more probiotic strains in vitro with an antagonistic activity on Candida yeasts and then to perform an in vivo human pilot study using an association of the most promising and active bacteria.
T he composition of the urogenital microflora is crucial for the health and well-being of women. 1 In the vaginal environment, many different groups of microorganisms, either commensals, opportunistic pathogens or probiotics, coexist in equilibrium with each other and with the guest. They are subject to qualitative and quantitative changes over the years and in response to both exogenous and endogenous factors. As the behavioral exposures may challenge the perpetuation of the Lactobacillus population, the intrinsic stability of the resident microflora is paramount to women's health. 2 Several factors can cause an imbalance in the vaginal microflora which, in turn, can lead to the onset of vaginitis or chronic forms of vaginosis. Very common are those resulting from unrestricted growth of yeasts belonging to the Candida genus, of which the most well-known species is represented by Candida albicans. This dimorphic yeast is a commensal that colonizes skin, the gastrointestinal, and the reproductive tracts. 3, 4 It is the main causative agent of mycotic vulvovaginitis, although in recent years infections caused by different species such as Candida glabrata, Candida tropicalis, Candida parapsilosis, and Candida krusei have steadily increased. 5, 6 The pathogenesis and prognosis of candidial infections are affected by the host immune status and also differ greatly according to disease presentations.
The incidence is very high, as 70% to 75% of women have at least 1 case of vulvovaginal candidiasis (VVC) during their life. 7, 8 Equally important is the fact that 40% to 50% of subjects have 1 or more recurrences after the apparent resolution of the first infective episode. 9 Moreover, 25% to 40% of women who are culture positive for the Candida species in the vaginal area are asymptomatic carriers. 10 VVC is regarded as an opportunistic infection of endogenous origin; therefore, it is not a sexually transmitted disease. 11 After bacterial vaginosis, VVC is the second in frequency among vaginitis, which are the leading cause of gynecologic examination in western countries. 12 The diagnosis should be made on the basis of clinical observations reported by the gynecologist and, if doubts remain, it must be confirmed by a microscopic assessment of fresh tissue and the execution of a microbial culture before starting a specific pharmacological therapy. 13 Some studies have identified some predisposing conditions that often, precisely by altering the balance of vaginal ecosystem, enable its development, the appearance of typical symptoms of the infection, and determine recurrences.
Contributing factors could be the use of antibiotics, cortisone, genetic and racial factors, diseases of the immune system, stress, diabetes, increased local temperature and moisture (wet swimsuits, wet linen at the gym), excessive use of douches and detergents, or a diet rich in glycogen and hormonal contraceptives. [14] [15] [16] [17] [18] Recurrences are more frequent in perimenstrual period.
Menopause, ageing, and pregnancy, due to the hormonal changes involved, are conditions able to encourage Candida growth. In fact, many women have their first episode or a relapse just during these periods. 19 Candida causes burning, itching, and discomfort and, in case of recurrences, often has a major impact on the quality of social, psychological, and sexual life of the woman.
Management approaches include treating each individual episode or using prophylactic antimycotic measures. 20 Previously, several prophylactic regimens were advocated that involved the use of intravaginal antimycotic agents either daily or weekly or oral ketoconazole for approximately 6 months. 21, 22 Although these measures are generally regarded as effective in the treatment of acute infections, they are frequently unable to offer a significant protection against possible recurrences of VVC. Furthermore, they are inconvenient and expensive, and oral ketoconazole was associated with an unacceptable risk of hepatotoxic effects. 23 In relapses, and as prophylaxis and prevention, the use of specific probiotic microorganisms is consolidating with the aim of restoring the physiological balance of vaginal ecosystem, mainly attributed to the presence of lactobacilli and the so-called Do¨derlein complex. 24 The use of live microorganisms with a probiotic value has, in fact, been indicated for some years by many gynecologists as an alternative or complementary therapy to the use of traditional topical medicines with antibacterial or antimycotic activity. 25 The oral and vaginal administration of probiotics is taken into account and considered useful also during pregnancy. 26 Probiotics are well known for their ability to lower the intravaginal pH, thus establishing a barrier effect against many types of yeasts. 27 Some strains are also able to exert additional and more focused antagonistic activities mediated by specific molecules such as hydrogen peroxide and bacteriocins. 28 For example, Lactobacillus fermentum LF5 (CNCM I-789) was successfully tested in 4 human trials involving a total of 340 women reporting VVC at enrollment (data not published).
In any case, the dosage form and strategy adopted to deliver probiotics to the vaginal environment represents a crucial point. Formulations based on oily probiotic suspensions are most often unable to guarantee the greatest efficacy of the beneficial bacteria used. For this reason, alternative forms have been recently investigated, specifically hydrogels, capsules, and tablets. 29 In light of the above, an association of probiotic strains was selected in vitro on the basis of their ability to directly antagonize different Candida species. As a second step, a combination of the 2 specific probiotic strains L. fermentum LF10 (DSM 19187) and Lactobacillus acidophilus LA02 (DSM 21717), administered in the form of a new commercial product, ActiCand 30, was investigated in vivo for its ability to create and maintain a vaginal microenvironment that did not encourage the establishment, propagation, or persistence of a Candida infection.
MATERIALS AND METHODS

In Vitro Assessment of the Antagonistic Activity of Selected Probiotic Strains Against Candida Yeasts
The in vitro inhibitory activity of 3 probiotic strains, namely L. fermentum LF10 (DSM 19187), L. fermentum LF11 (DSM 19188), and L. acidophilus LA02 (DSM 21717), against 5 yeasts belonging to 4 different Candida species was quantified at the Biolab Research (Novara, Italy).
The probiotic strains used were characterized at the species level by species-specific polymerase chain reaction using the primers Lfpr/Ferm II for L. fermentum, 30 and ACI/16S II for L. acidophilus. 31 With regard to the individual biotypes, the molecular fingerprinting was obtained using a pulsed-field gel electrophoresis analysis for all strains. 32 More specifically, C. albicans ATCC 10231, C. parapsilosis ATCC 22019, C. krusei ATCC 6258, C. albicans ATCC 90028, and C. glabrata ATCC 2001 were used. The inhibitory results of fresh broth cultures of individual probiotic strains grown overnight in De Man, Rogosa, and Sharpe (MRS) broth (Merck Chemicals, Milan, Italy) were compared with freeze-dried cultures of the same bacteria. In particular, fresh broth cultures were used with all Candida strains, whereas freeze-dried samples were tested against C. albicans ATCC 10231, chosen as an indicator of activity. Before being used in the experiment, individual Candida strains were grown in Sabouraud Dextrose Broth (BD Italia, Milan, Italy), an optimal medium for yeasts, for 48 hours in aerobic conditions. Each probiotic was then cocultured in the same broth (MRS) inoculated with one of the above-mentioned Candida microorganism. The ratio between the inocula of probiotic and yeast was 1:3 in favor of the latter. Incubation was performed in aerobiosis at 371C for 48 hours. Each culture (1 mL) was sampled after 24 and 48 hours of incubation for the selective enumeration of the yeasts, performed on Yeast extract glucose chloramphenicol (YGC) agar medium (Sigma-Aldrich, Milan, Italy). YGC agar plates were incubated in aerobic conditions at 251C for 24 to 48 hours to allow the growth of any yeast present. Colonies were then counted and results expressed as number of colony-forming units (CFU)/mL.
In Vivo Study Design
Thirty female patients (age between 23 and 64 y, mean 40.9 ± 11.1, menopausal women 8) were enrolled in the study between May and June 2011 at the Casa di Cura "San Pio X" Private Clinic (Milan, Italy). Informed written consent was obtained from all participants involved in the study.
Eligible subjects were at least 18 years old, had active, acute vulvovaginal candidiasis (total severity score = 3), had a positive result from microscopic examination of vaginal secretions with 10% potassium hydroxide; and had at least 4 documented episodes of vulvovaginal candidiasis in the last 12 months.
The severity score was based on the presence of symptoms (eg, itching, irritation, and burning) and vulvovaginal signs (eg, erythema, edema, and excoriation, or fissures). The severity of each sign or symptom was scored on a scale of 0 (absent or normal) to 3 (severe). 33 The level of vulvovaginal discharge was not scored.
Patients were excluded from the study if the microscopic findings could not be confirmed by culture. Other exclusion criteria were pregnancy, mixed infections, known seropositivity for the human immunodeficiency virus, and treatment with antifungal agents or other probiotic-containing products, even if taken orally, in the previous 2 months.
After enrollment in the study, all patients received the product ActiCand 30 (Probiotical, Novara, Italy), formulated in slow release, slightly effervescent vaginal tablets containing at least 0.4 billion live cells of each probiotic L. fermentum LF10 and L. acidophilus LA02. In addition, each tablet contained 273 mg of arabinogalactan and 332 mg of fructo-oligosaccharides, 2 prebiotic fibers used to enhance vaginal colonization by the 2 probiotics. The slight effervescence was mediated by the presence of 64 mg of citric acid and 56 mg of sodium bicarbonate and was particularly intended to rapidly create an anaerobic vaginal microenvironment able to favor the growth of probiotics and, on the other side, to exert a barrier effect against Candida yeasts that, for the fact of being respirer microorganisms, are unable to grow in anaerobic conditions. 34 The protocol adopted was mostly in accordance with the instructions for use of the commercial product; therefore, patients were directed to apply a vaginal tablet once a day for 7 consecutive nights, preferably before going to bed. Then, to maintain the vaginal colonization by the 2 probiotics, patients used 1 tablet every 3 nights for a further 3-week application. The acute treatment lasted, therefore, for 4 weeks in total. In the following month, to maintain a long-term vaginal colonization against possible recurrences, patients used 1 tablet per week.
Patients were prohibited from using topical vaginal or other systemic antifungal agents at any time during the study. They were also prohibited from using antibiotics or other probiotic products, even if taken orally, throughout the duration of the study.
A vaginal medical examination of each patient, which included obtaining vaginal swabs for yeast culture, was directly performed at the Gynaecology Unit of the Private Clinic at baseline, at the end of the first 4 weeks of treatment and at the end of the second month of relapses prevention.
Collection of Vaginal Swabs and Yeast Cultures
At each visit (baseline, d 0 ; end of the acute treatment, d 28 ; end of the second month, d 56 ), vaginal swabs were obtained for culture. Once a swab sample was collected, it was placed immediately into a polypropylene screw-cap ESwab transport tube filled with 1 mL of Liquid Amies transport medium (BD Italia), stored at 41C and delivered to the laboratory within 24 hours after collection. On receipt of clinical isolates, the ESwab specimen tubes were briefly vortexed, and then the swab was removed according to the manufacturer's instructions. Swab medium (100 mL) was inoculated onto Yeast extract dextrose chloramphenicol (YGC) agar (Sigma-Aldrich). All the agar plates were incubated in aerobic conditions at 251C for 24 to 48 hours to allow the growth of any yeast present.
A subsequent identification at the species level was performed with the use of the API 20C AUX system (BioMerieux, Florence, Italy). More specifically, 2 yeast colonies were picked from each agar plate, individually inoculated in molten (501C) API basal medium ampoules and each suspension was standardized to a density below 1 + (lines can be clearly distinguished) on a Wickerham card. Each cupule of the strip was inoculated (20 cupules; approximately 0.2 mL each) by using a Pasteur pipette, and the trays were incubated for 72 hours at 301C. Cupules showing turbidity significantly higher than that of the negative control cupule (cupule "0") were considered positive. Identification was made by generating a microcode and using the API 20C AUX Analytical Profile Index. 35 2 colonies were used to be more confident of the result.
The assessment of the presence of yeasts in vaginal swabs, and Candida identification at the species level, were performed at the Biolab Research.
Statistical Analysis
A subject positive for Candida infection, as confirmed by both microscopic examination and yeast culture, was marked with "X". Paired t test statistical analysis was used to weigh the results and compare them between d 28 and d 0 , d 56 and d 0 , and d 56 and d 28 . Differences were considered significant at Pr0.05.
RESULTS
In Vitro Antagonistic Activity of Selected Probiotic Strains Toward Candida Yeasts
The molecular fingerprinting of the 3 strains investigated for their in vitro activity against Candida is reported in Figure 1 .
All the probiotics demonstrated considerable antagonistic activity against the 5 Candida strains tested, with the 2 L. fermentum significantly more effective than L. acidophilus LA02. No significant differences were recorded between fresh broth cultures and freeze-dried samples of each probiotic bacterium, thus demonstrating that, despite a reasonable moderately longer lag phase at the very beginning of incubation, the ability of a probiotic bacterium to antagonize a specific target microorganism could also be entirely exerted by a freeze-dried culture, the form commonly used in commercial products. The results are expressed as percentages of inhibition of Candida growth after 24 and 48 hours of incubation and as inhibition extent expressed as log 10 . A comparison between viable cell counts of Candida after 24 or 48 hours and time 0 inoculum is included as well (Table 1) . L. acidophilus LA02 was included as a negative control, which is a probiotic able to exert only unspecific inhibitory effects exclusively mediated by the organic acids produced and the consequent pH lowering. As L. acidophilus species has a homofermentative metabolism, the sole organic acid produced is lactic.
The most relevant differences were recorded after 24 hours, with L. acidophilus LA02 generally able to inhibit the growth of only 56.7% to 93.3% of Candida cells compared with samples of yeast cultured alone. L. fermentum LF10 and LF11 were able to inhibit not <98% of Candida at 24 hours, with the average values around 99.8%.
The differences are considerably more appreciable if expressed as base-10 logarithms, ranging from 1.70 to 4.19 after 24 hours for the 2 L. fermentum compared with 0.37 to 1.17 recorded with L. acidophilus LA02. Moreover, at 24 hours, a significant Candida growth was observed when cocultured with L. acidophilus LA02 (variation vs. time 0 from 83.9 to 2,280 times), whereas no significant growth compared with inoculum was recorded with any of the L. fermentum used. In fact, variations ranged from 0.10, meaning a 10-time decrease, to 61.0 recorded with C. glabrata ATCC 2001, apparently the most resistant yeast strain.
After 48 hours, L. acidophilus LA02 was able to cause a slight mortality of only C. krusei ATCC 6258 (variation vs. time 0 = 0.8), whereas all the other Candida strains were able to grow (variation vs. time 0 ranging from 24.9 to 1170). In any case, Candida viable cell counts were always higher at 24 hours compared with 48 hours, meaning that the lactic acid produced by L. acidophilus LA02 needs a certain period of time to unspecifically restrict yeast growth.
In contrast, both L. fermentum probiotics showed a very strong inhibition of all Candida after 48 hours. In many samples, <10 CFU/mL of broth were retrieved. C. parapsilosis ATCC 22019 seemed to be the relatively most resistant strain, even if 3.5 base-10 logarithms of inhibition were recorded with both L. fermentum compared with 1.46 mediated by L. acidophilus. Figure 2 reports the growth kinetics of C. albicans ATCC 10231 cultured either alone or in the presence of individual probiotics used as freeze-dried samples.
Results from freeze-dried cultures, assessed using C. albicans ATCC 10231 as indicator of activity, are similar to values recorded with fresh broth cultures, therefore suggesting that the physical status of the bacterial population is not able to quantitatively influence its ability to exert a strong protective barrier effect against Candida. The higher inoculum of C. albicans ATCC 10231 compared with the previous experiment made the difference in inhibition extents even more significant between both L. fermentum and L. acidophilus.
Results of the In Vivo Human Efficacy Study
All female patients completed the treatment, meaning there were no drop-outs, thus confirming the very high tolerability profile of the product ActiCand 30. In the examination at the end of the first 4 weeks of product application, performed by both microscopic assessment and yeast culture, a complete healing and disappearance of Candida infection was found in 26 patients out of 30 (corresponding to 86.6%, P < 0.001) ( Tables 2 and 3) . Furthermore, no recurrence occurred or was reported after the first week of treatment with 1 tablet a day, thus suggesting that the application of 1 tablet every 3 nights for a further 3-week period is sufficient to completely prevent relapses when the probiotics of ActiCand 30 are already integrated in the vaginal microbiota.
At the end of the second month, during which patients were directed to apply 1 tablet every 7 days, a recurrence episode was recorded, albeit not particularly serious, in only 3 out of 26 patients (11.5%, P = 0.083) who were found to have fully healed at the end of the first month of treatment. In any case, the statistical comparison between results at the end of the second month and time 0 is still significant (P < 0.001) ( Table 3) .
The Candida species responsible for VVC diagnosed at enrollment were identified (Table 4 ).
DISCUSSION
The in vitro inhibitory results strongly suggested that the mechanism of action of the L. fermentum probiotics is at least partially based on specific molecules other than organic acids, such as bacteriocins, extracellular proteins, or hydrogen peroxide. In other words, acidity alone did not inhibit the growth of individual Candida strains to the same extent as L. fermentum LF10 and LF11. The major difference was that L. acidophilus LA02 was only able to limit the growth of Candida in coculture compared with the yeast alone, whereas both L. fermentum not only prevented any significant growth of Candida at 24 hours, but also exerted a noticeable microcidal activity at 48 hours. One of the 2 L. fermentum strains was chosen to formulate the new vaginal probiotic product ActiCand 30 together with L. acidophilus LA02, used to more extensively restore the vaginal Do¨derlein complex. 36 In defining the formulation of a vaginal product, it should always be taken into account that the way used to deliver probiotics to the vaginal environment is a crucial point.
The results collected from this human efficacy pilot study demonstrate the effectiveness of ActiCand 30 in the establishment and maintenance of a protective barrier effect against vaginal Candida, well known as the causative agent of even severe vaginitis, able to relapse and heavily compromise the overall quality of life of the women affected.
The results showed that most yeast infections were caused by the C. albicans species (80.0%), and this is consistent with the findings reported in literature. Two out of 3 relapses recorded in the second month of the study protocol were to be ascribed to C. albicans and the remaining to the C. krusei species, even if this was not a real relapse of the same preexistent infection. At enrollment, no positive C.
krusei yeast culture was found. The woman who experienced a C. krusei positive result at d 56 was diagnosed with a C. albicans infection at d 0 . This infection was found to have fully healed at the end of the first month (d 28 ) of treatment; therefore, this should be more properly regarded as a new infection case rather than a classic recurrence. In any case, the number of C. krusei cells enumerated on YGC agar was <10 and also the visual examination of the vaginal mucosa suggested a very mild infection.
The compliance and tolerability profile were very good, as no drop-out was recorded during the entire study protocol.
ActiCand 30 was specifically formulated in slow release effervescent tablets to rapidly create an anaerobic vaginal microenvironment after application, able to be reasonably maintained for at least 40 to 60 minutes, because the disaggregation time of a single tablet is around 30 minutes. Anaerobiosis is well known to encourage the colonization and proliferation of lactobacilli and Do¨derlein endogenous biota in general, while restricting the growth of Candida spp. in light of their respirer yeast feature.
In contrast, a longer time is needed for the establishment of the protective barrier effect exerted by the 2 probiotics L. fermentum LF10 and L. acidophilus LA02. wNumber of base-10 logarithms of inhibition mediated by each probiotic after either 24 or 48 hours of incubation. Values <1 show inhibition of <1 order of magnitude, whereas values >1 mean a decrease in the number of Candida cells at least >10 times. The comparison was made with the number of Candida cells grown alone after the same period of time.
zNumber of times of change with respect to time 0 (inoculum). Values <1 show a decrease in the number of yeasts, whereas numbers >1 mean a growth of the Candida tested compared with its time 0 inoculum.
In summary, 2 specific chronologically distinct actions are mediated by ActiCand 30:
Short-term barrier effect exerted by the CO 2 released during the slow disaggregation of the tablet. CO 2 is also able to partly lower the vaginal pH after hydration and subsequent formation of carbonic acid, which is a diprotic acid that may dissociate into bicarbonate ion, HCO 3 À , and H + ; Long-term protective barrier effect guaranteed by the vaginal microbiota colonization by the 2 probiotics, able to restore the Do¨derlein complex, habitually compromised in case of candidiasis. These beneficial bacteria are able to mediate both a mechanical action (competition for adhesion sites to the mucosa) and a metabolic activity consisting of the production of organic acids and other more specific molecules, especially bacteriocins. 37 Also of particular interest is the product's ability to prevent recurrences, a very common issue in VVC. The overall effectiveness of ActiCand 30 could be regarded as very similar to most commercial products traditionally and historically used to treat or prevent vulvovaginitis by Candida. Furthermore, this product has the valuable advantage of the lack of any adverse side-effect, because lactobacilli are an integral and desirable part of the endogenous vaginal microbiota.
Further assessments will be needed to completely identify and characterize the molecules at the basis of the mechanism of action of L. fermentum LF10 and LF11 toward Candida yeasts. In any case, this study further strengthens the evidence supporting the use of specific probiotic strains with well-demonstrated activities for the Growth kinetics of C. albicans ATCC 10231 alone and in the presence of different probiotic strains 
